The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Velnacrina     9-amino-1,2,3,4- tetrahydroacridin-1-ol

Synonyms: Velnacrine, Velnacrinum, CHEMBL51934, SureCN194467, AG-J-38179, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Velnacrine

  • The effect did not co-vary with the degree of memory improvement, but, instead, more cognitively impaired patients showed a greater increase in tracer uptake after velnacrine, suggesting cholinergic hypersensitivity in the brains of Alzheimer patients [1].
  • THA and velnacrine were also tested in a rat hepatoma cell line (H4) and in primary dog hepatocytes [2].
 

Psychiatry related information on Velnacrine

 

High impact information on Velnacrine

 

Chemical compound and disease context of Velnacrine

 

Biological context of Velnacrine

 

Anatomical context of Velnacrine

 

Associations of Velnacrine with other chemical compounds

 

Gene context of Velnacrine

  • With one acetylcholinesterase (AChE) inhibitor compound (velnacrine), we found that AD patients tolerated considerably lower dosages than young normals and healthy elderly subjects, whereas our findings were exactly the opposite with another AChE inhibitor (eptastigmine) [17].
  • Both studies reported a significant benefit for velnacrine compared with placebo for the ADAS-cog, but the results could not be checked because the relevant information was not reported [6].
 

Analytical, diagnostic and therapeutic context of Velnacrine

References

  1. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Ebmeier, K.P., Hunter, R., Curran, S.M., Dougal, N.J., Murray, C.L., Wyper, D.J., Patterson, J., Hanson, M.T., Siegfried, K., Goodwin, G.M. Psychopharmacology (Berl.) (1992) [Pubmed]
  2. Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. Viau, C.J., Curren, R.D., Wallace, K. Drug and chemical toxicology. (1993) [Pubmed]
  3. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Antuono, P.G. Arch. Intern. Med. (1995) [Pubmed]
  4. Velnacrine maleate improves delayed matching performance by aged monkeys. Jackson, W.J., Buccafusco, J.J., Terry, A.V., Turk, D.J., Rush, D.K. Psychopharmacology (Berl.) (1995) [Pubmed]
  5. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Zemlan, F.P., Keys, M., Richter, R.W., Strub, R.L. Life Sci. (1996) [Pubmed]
  6. Velnacrine for Alzheimer's disease. Birks, J., Wilcock, G.G. Cochrane database of systematic reviews (Online) (2004) [Pubmed]
  7. Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro. Braga, M.F., Harvey, A.L., Rowan, E.G. Br. J. Pharmacol. (1991) [Pubmed]
  8. Amperometric measurements of nitric oxide in erythrocytes. Carvalho, F.A., Martins-Silva, J., Saldanha, C. Biosensors & bioelectronics. (2004) [Pubmed]
  9. Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease. Butterfield, D.A., Rangachari, A. Biochem. Biophys. Res. Commun. (1992) [Pubmed]
  10. Identification of the urinary metabolites of tacrine in the rat. Hsu, R.S., Shutske, G.M., Dileo, E.M., Chesson, S.M., Linville, A.R., Allen, R.C. Drug Metab. Dispos. (1990) [Pubmed]
  11. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. Puri, S.K., Ho, I., Hsu, R., Lassman, H.B. Journal of clinical pharmacology. (1990) [Pubmed]
  12. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease. Wood, D.M., Ford, J.M., Roberts, C.J. Eur. J. Clin. Pharmacol. (1996) [Pubmed]
  13. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. Hardiman, S., Miller, K., Murphy, M. Acta Neurol. Scand., Suppl. (1993) [Pubmed]
  14. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. Puri, S.K., Hsu, R.S., Ho, I., Lassman, H.B. Journal of clinical pharmacology. (1989) [Pubmed]
  15. Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate. al Casey, S., Brewster, D., Viau, C., Acosta, D. Toxicol. Lett. (1995) [Pubmed]
  16. The effect of velnacrine on the mixed function oxidase system. Eccles, M.J., Danbury, T.C., Ford, J.M., Roberts, C.J. European journal of drug metabolism and pharmacokinetics. (1997) [Pubmed]
  17. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study". Cutler, N.R., Sramek, J.J. Alzheimer disease and associated disorders. (1995) [Pubmed]
  18. Determination of velnacrine in plasma and urine by high-performance liquid chromatography. Hsu, R.S., DiLeo, E.M., Chesson, S.M., Ellis, D.B., Wichmann, J.K. J. Chromatogr. (1989) [Pubmed]
 
WikiGenes - Universities